Cite
A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
MLA
Byrne, Barry J., et al. “A Study on the Safety and Efficacy of Reveglucosidase Alfa in Patients with Late-Onset Pompe Disease.” Orphanet Journal of Rare Diseases, vol. 12, Aug. 2017, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s13023-017-0693-2.
APA
Byrne, B. J., Geberhiwot, T., Barshop, B. A., Barohn, R., Hughes, D., Bratkovic, D., Desnuelle, C., Laforet, P., Mengel, E., Roberts, M., Haroldsen, P., Reilley, K., Jayaram, K., Ke Yang, Walsh, L., Yang, K., & POM-001/002 Investigators. (2017). A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease. Orphanet Journal of Rare Diseases, 12, 1–10. https://doi.org/10.1186/s13023-017-0693-2
Chicago
Byrne, Barry J., Tarekegn Geberhiwot, Bruce A. Barshop, Richard Barohn, Derralynn Hughes, Drago Bratkovic, Claude Desnuelle, et al. 2017. “A Study on the Safety and Efficacy of Reveglucosidase Alfa in Patients with Late-Onset Pompe Disease.” Orphanet Journal of Rare Diseases 12 (August): 1–10. doi:10.1186/s13023-017-0693-2.